WO2019103662A3 - Амид-содержащие производные 2-оксиндола, способ их получения и применения - Google Patents

Амид-содержащие производные 2-оксиндола, способ их получения и применения Download PDF

Info

Publication number
WO2019103662A3
WO2019103662A3 PCT/RU2018/050152 RU2018050152W WO2019103662A3 WO 2019103662 A3 WO2019103662 A3 WO 2019103662A3 RU 2018050152 W RU2018050152 W RU 2018050152W WO 2019103662 A3 WO2019103662 A3 WO 2019103662A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
nhс
heteroaryl
nhc
Prior art date
Application number
PCT/RU2018/050152
Other languages
English (en)
French (fr)
Other versions
WO2019103662A2 (ru
Inventor
Екатерина Витальевна ЗАРЯНОВА
Наталья Александровна ЛОЗИНСКАЯ
Ольга Валерьевна БЕЗНОС
Никита Николаевич ИВАНОВ
Дарья Всеволодовна ЗАХАРОВА
Дмитрий Александрович ШУЛЬГА
Наталья Борисовна ЧЕСНОКОВА
Original Assignee
Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" filed Critical Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова"
Publication of WO2019103662A2 publication Critical patent/WO2019103662A2/ru
Publication of WO2019103662A3 publication Critical patent/WO2019103662A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C409/00—Peroxy compounds
    • C07C409/02—Peroxy compounds the —O—O— group being bound between a carbon atom, not further substituted by oxygen atoms, and hydrogen, i.e. hydroperoxides
    • C07C409/04—Peroxy compounds the —O—O— group being bound between a carbon atom, not further substituted by oxygen atoms, and hydrogen, i.e. hydroperoxides the carbon atom being acyclic
    • C07C409/08—Compounds containing six-membered aromatic rings
    • C07C409/12—Compounds containing six-membered aromatic rings with two alpha,alpha-dialkylmethyl hydroperoxy groups bound to carbon atoms of the same six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложены соединения общей формулы (I): где R1 означает Н, бензил, C1-C4-алкил; R2 означает H, OH, OR6; R3 означает СООН, CN; R4 означает H, OC1-C4-алкил, галоген, C1-C4-алкил, COOC1-C4-алкил, NHC(X)R7; R5 означает С3-С6-циклоалкил, C5-C6-арил, C5-C6-гетероарил, NHС1-С4-алкил, NHС1- С4-галоидалкил, NHС3-С6-циклоалкил, NHC5-C6-арил, NHC5-C6-гетероарил, OC5-C6- арил, где С5-С6-гетероарил означает 5-6-членный арил с 1 или 2 гетероатомами, выбранными из группы O, N, S; R6 означает C1-C4-алкил, C(O)C1-C4-алкил; R7 означает С1-С4-алкил, С1-С4-галоидалкил, OC1-C4-алкил, С3-С6-циклоалкил, C5-C6- арил, C5-C6-гетероарил, NHС1-С4-алкил, NHС1-С4-галоидалкил, NHС3-С6- циклоалкил, NHC5-C6-арил, NHC5-C6-гетероарил, OC5-C6-арил, где С5-С6-гетероарил означает 5-6-членный арил с 1 или 2 гетероатомами, выбранными из группы O, N, S; X означает O, S; и его стереоизомеры и фармацевтически приемлемые соли, способ 5 получения данных соединений и их применение в качестве лекарственных средств, в качестве компонента фармацевтической композиции для лечении офтальмологических заболеваний, а также способ лечения офтальмологических заболеваний с использованием фармацевтической композиции на основе соединений формулы (I).
PCT/RU2018/050152 2017-11-27 2018-11-27 Амид-содержащие производные 2-оксиндола, способ их получения и применения WO2019103662A2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017141181A RU2685501C1 (ru) 2017-11-27 2017-11-27 Амидсодержащие производные 2-оксиндола, способ их получения и применения
RU2017141181 2017-11-27

Publications (2)

Publication Number Publication Date
WO2019103662A2 WO2019103662A2 (ru) 2019-05-31
WO2019103662A3 true WO2019103662A3 (ru) 2019-07-25

Family

ID=66168175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2018/050152 WO2019103662A2 (ru) 2017-11-27 2018-11-27 Амид-содержащие производные 2-оксиндола, способ их получения и применения

Country Status (2)

Country Link
RU (1) RU2685501C1 (ru)
WO (1) WO2019103662A2 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112142645B (zh) * 2019-06-27 2021-12-24 山东大学 含脲结构的二酮吲哚类化合物及其制备方法和应用
CN111018871A (zh) * 2019-12-30 2020-04-17 天津科技大学 一类具有抗肿瘤活性的5-酰胺基取代的靛红类衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712036C2 (ru) * 2017-01-30 2020-01-24 Сергей Евгеньевич Сосонюк Производные индолинона, обладающих свойствами лигандов мелатонинового рецептора и их применение

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHESNOKOVA N.B. ET AL.: "Vliyanie instilliatsy melatonina na kharakter techenia eksperimentalnogo uveita i biokhimicheskie protsessy v sleznoi I vnutriglaznoi zhidkostiakh", BIOMEDITSINSKAYA KHIMIA, vol. t.62, no. 2, 2016, pages 164 - 168 *
ZARYANOVA E. V. ET AL.: "Oxindole-based intraocular pressure reducing agents.", BIOORG MED CHEM LETT., vol. 27, no. 16, 2017, pages 3787 - 3793, XP085144526, DOI: 10.1016/j.bmcl.2017.06.065 *
ZARYANOVA E. V. ET AL.: "Synthesis and reactivity of new amide- substituted oxindole derivatives", TETRAHEDRON, vol. 73, no. 49, 20 October 2017 (2017-10-20), pages 6887 - 6893, XP085282005, DOI: 10.1016/j.tet.2017.10.049 *

Also Published As

Publication number Publication date
WO2019103662A2 (ru) 2019-05-31
RU2685501C1 (ru) 2019-04-19

Similar Documents

Publication Publication Date Title
WO2018064632A8 (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2017035353A8 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
JOP20190125A1 (ar) مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
JOP20200178A1 (ar) حلقات ضخمة كمعدلات لمنظم توصيل التليف الكيسي عبر الغشاء، وتركيبات صيدلانية منها، واستخدامها في علاج التليف الكيسي، وعملية لتصنيعها
WO2019173082A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
MX2020000268A (es) Agonista de fxr.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
MX2023005099A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
MX2020009062A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos.
WO2017127430A8 (en) Irak4 inhibiting agents
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2020011845A (es) Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
WO2017177004A8 (en) Tertiary amides and method of use
PH12021550713A1 (en) Medicament for the treatment of chronic cough
WO2019103662A3 (ru) Амид-содержащие производные 2-оксиндола, способ их получения и применения
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
WO2020092127A8 (en) Novel sting agonists
WO2020210481A8 (en) Heterocyclic compounds as kinase inhibitors for therapeutic uses
NO20065551L (no) Anvendelse av opoid reseptor antagonistforbindelser for forhindring og/eller behandling av sykdommer assosiert med malet calcineurin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18881952

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18881952

Country of ref document: EP

Kind code of ref document: A2